STENOCARE Welcomes Danish Health Minister’s Decision to Permanently Legalise Medical Cannabis for Patients

The Danish Pilot Programme for medical cannabis is set to become a permanent legalisation for the treatment of Danish patients, according to the government. Today, the Danish Health Minister in…

STENOCARE Welcomes Danish Health Minister’s Decision to Permanently Legalise Medical Cannabis for Patients

The Danish Pilot Programme for medical cannabis is set to become a permanent legalisation for the treatment of Danish patients, according to the government. Today, the Danish Health Minister invited political parties to discuss the permanent legalisation of medical cannabis in Denmark. This is excellent news for Danish patients and Stenocare, as it secures future access to and sales of medical cannabis in Denmark.

Stenocare sees this as a victory for Danish patients, Stenocare and the medical cannabis industry. The permanent legalisation will provide certainty for patients' continued treatment with medical cannabis, as it will no longer be limited to a temporary pilot programme. For the industry, the permanent legalisation will establish a clear framework for the future, offering clarity beyond December 2025 and justify investments in new products that deliver value to both doctors and patients.

Stenocare CEO, Thomas Skovlund Schnegelsberg, is commenting:

“Stenocare has been a leading supplier of medical cannabis products to the Danish Pilot Programme since 2018. The programme has provided valuable insights into the regulatory framework, patient treatment, the prescription process, and product subsidies. It is excellent news for patients and Stenocare that the government is now taking steps toward permanent legalisation. We were invited to provide input for the pilot evaluation report, which politicians will use in their work to define a permanent legalisation model for Denmark. We are confident that the future of medical cannabis treatment is in good hands.”

STENOCARE A/S and ADREXpharma are now ready to deliver a new and innovative medical cannabis oil product for German patients, that has the potential to revolutionize the market.

Stenocare and ADREXpharma have received approval to sell a new and innovative medical cannabis oil product in Germany, set…

STENOCARE A/S and ADREXpharma are now ready to deliver a new and innovative medical cannabis oil product for German patients, that has the potential to revolutionize the market.

Stenocare and ADREXpharma have received approval to sell a new and innovative medical cannabis oil product in Germany, set to be available for patients in the fourth quarter of 2024. 

The new product is a THC-CBD 10-10 oil in a 30 ml bottle which has the potential to address a large target group of patients in the German market. Stenocare has since 2019 been investing with partners to develop and test next generation medical cannabis oil products, that can position Stenocare as a true leader within prescription-based medical cannabis. The new product-line is branded “Astrum”, and the company has worldwide exclusivity for this patented oil technology. The company is now ready to commercialize the product in the second market (Germany). The official German product name is “Astrum 10-10 Ext Stenocare”, with 10 mg/ml THC and 10 mg/ml CBD.

Innovative product: The Stenocare Astrum product is based on an innovative oil technology, that has the potential to increase the cannabinoid’s bioavailability in the patient’s blood. Thereby, the new product is addressing a well-known challenge with dosing medicine and securing consistent uptake of the active ingredients in the blood. With the Astrum product, Stenocare has completed a pharmacokinetic (PK) study in dogs that documented two important parameters in the lymphatic system that can improve the bioavailability. Read the full press release: 2930524.pdf (cision.com)

STENOCARE is expanding into Canada

Stenocare is partnering with a team of industry experts in Canada. Stenocare is one of the first European medical cannabis companies to enter Canada. In support of this growth strategy, the company has partnered with some of Canada’s leading medical cannabis innova…

STENOCARE is expanding into Canada

Stenocare is partnering with a team of industry experts in Canada. Stenocare is one of the first European medical cannabis companies to enter Canada. In support of this growth strategy, the company has partnered with some of Canada’s leading medical cannabis innovators.

Stenocare is planning to introduce its innovative “Astrum” oil product in the Canadian market. The Canadian medical market has seen very little investment focused on patient and consumer-facing innovation, and this offers Stenocare an opportunity to become a leader with a patient-first approach to medication delivery. Since 2019, Stenocare has been investing with partners to develop and test next-generation medical cannabis oil products, positioning Stenocare as a true leader within prescription-based medical cannabis. The new product line is branded “Astrum,” and the company has worldwide exclusivity for this patented oil technology. The company is shortly commercializing its first Astrum 10-10 oil in Australia.

For full press release: https://stenocare.com/inv.../announcements/C89EA916C890B1BB/

An Update on Stenocare's Strong Product Pipeline

Since 2019, Stenocare has invested in qualifying and developing the new and innovative ASTRUM Oil product. Through a pharmacokinetic study with dogs, it has documented improved bioavailability in the blood, enhanced uniformity of uptake, and reduced t…

An Update on Stenocare's Strong Product Pipeline

Since 2019, Stenocare has invested in qualifying and developing the new and innovative ASTRUM Oil product. Through a pharmacokinetic study with dogs, it has documented improved bioavailability in the blood, enhanced uniformity of uptake, and reduced time for maximum uptake. Bringing true innovation to the market is a multi-year investment, and the Australian market is the first to benefit from this new product in Q3 2024. Stenocare continues its efforts in developing ASTRUM Oil for new markets.

For full press release: https://stenocare.com/inv.../announcements/2643F521B980B975/

Product innovation: STENOCARE launch next generation medical cannabis oil product in Australia – six months ahead of schedule. The new Astrum brand is an innovative cannabis oil product featuring a patented oil technology that enhances the bioavailability of its active ingredients. This breakthroug…

Product innovation: STENOCARE launch next generation medical cannabis oil product in Australia – six months ahead of schedule. The new Astrum brand is an innovative cannabis oil product featuring a patented oil technology that enhances the bioavailability of its active ingredients. This breakthrough allows for higher uptake in the blood, and reduced dosage requirements.

For full press release:

https://stenocare.com/inv.../announcements/C2D62E176A037DE2/

STENOCARE is sharing early information about the upcoming share issue “TO2 Warrant” transaction in June 2024

STENOCARE A/S (“Stenocare”) announced a year ago (May 2023) that the company would raise capital through three different share issue transactions. The last of these transactions is the upcomi…

STENOCARE is sharing early information about the upcoming share issue “TO2 Warrant” transaction in June 2024

STENOCARE A/S (“Stenocare”) announced a year ago (May 2023) that the company would raise capital through three different share issue transactions. The last of these transactions is the upcoming “TO2 Warrant” transaction, starting on June 10, 2024. Important: Only owners of TO2 Warrants will be able to subscribe (buy) new Stenocare shares at a 30% discount during the transaction window from June 10-21.

Stenocare like to highlight the following points about the TO2 Warrant transaction:

• Owning TO2 Warrants is a requirement for subscribing to the new Stenocare shares with a discount of 30%.
• Shareholders that subscribed for the Stenocare UNIT Right Issue during May/June 2023 also received TO2 Warrants that can now be exercised (used) or sold to the market.
• Becoming an owner of TO2 Warrants: TO2 Warrants are being traded daily and can be purchased or sold under ticker “STENO TO 2” or using the ISIN code DK0062493615.
• Each TO2 Warrant owned, entitles the owner subscribe (buy) one new Stenocare share with a discount of 30%.
• The discount arises as the subscription price for the new shares is calculated as subtracting a 30% discount of the 10-day volume weighted average price of the Stenocare mother share as traded on Nasdaq First North Growth Market Denmark in the period May 27 to June 7. The price will be announced on June 7, 2024 (after 17:00 Central European Time).
• TO2 Warrants that are NOT sold or used to subscribe for new shares with a discount before June 21 (time 17:00 CET) will become void.

Stenocare is advising current owners of TO2 Warrants to actively decide how to use their warrants.  Start by checking the actual number of TO2 Warrants owned in your account. There are four different options:

1.      Use all the TO2 Warrants to subscribe for new Stenocare shares at a 30% discount during June 10-21.

2.      Use all the TO2 Warrants and purchase additional TO2 Warrants to subscribe for more Stenocare shares at a discount.

3.      Use only part of the TO2 Warrants for new Stenocare shares at a discount and sell the remaining TO2 Warrants before June 19, 2024.

4.      Decide not to use the TO2 Warrants and sell all TO2 Warrants before June 19, 2024.

Information about the upcoming TO2 Warrant is available on the investor homepage: https://stenocare.com/to2-warrant-introduction/

Stenocare leadership role:

Our CEO, Thomas Skovlund Schnegelsberg, has been invited to serve as a judge for the upcoming 'Business of Cannabis Awards' on June 25, where industry leaders will celebrate individuals and organizations that have made significant contributions to the cannabis industry.

Th…

Stenocare leadership role:

Our CEO, Thomas Skovlund Schnegelsberg, has been invited to serve as a judge for the upcoming 'Business of Cannabis Awards' on June 25, where industry leaders will celebrate individuals and organizations that have made significant contributions to the cannabis industry.

The huge award event is hosted by the leading European industry media "Business of Cannabis" in London, where leaders within the medical cannabis industry are reviewing nominations for the ten award categories.

Denmark: The new STENOCARE THC/CBD medical cannabis oil product is now available for sale in Denmark

Starting today the new product is available for sales to patients, and Stenocare is the only supplier of THC/CBD oil products under the Pilot Programme. Out of the many suppliers seeking approval to …

Denmark: The new STENOCARE THC/CBD medical cannabis oil product is now available for sale in Denmark

Starting today the new product is available for sales to patients, and Stenocare is the only supplier of THC/CBD oil products under the Pilot Programme. Out of the many suppliers seeking approval to sell their products, Stenocare has been in a clear leadership position from the start of the Pilot in 2018 and is the only supplier of three different medical cannabis oil products under the Pilot.

Sales can begin: STENOCARE has successfully imported the first batch of a new medical cannabis oil product into Denmark. The new product is a combination THC/CBD oil containing 15 mg/ml THC and 24 mg/ml CBD with dosing delivered via an oral syringe. The new product is available starting today via pharmacies and requires a prescription.

Strong product portfolio: Stenocare is the first and so far, only supplier of this THC/CBD oil product for the Danish Pilot Programme. With this, Stenocare now once again has the complete portfolio of three medical cannabis oil products (ie. THC30 oil, CBD20 oil and now the THC/CBD oil). With this new product, Stenocare is able to offer the complete range of oil products they successfully sold to patients during 2018 and 2019, that grew the company sales and allowed the Company to reach breakeven in Q1 2019. Therefore, having this complete product range for the Danish Pilot Programme is an important element in the 2024 ambitions to once again reach breakeven at the end of the year.

Stenocare CEO Thomas Skovlund Schnegelsberg comments:

“Today we make yet another medical cannabis oil product available for patients. We now offer three different oil products, that together are addressing therapeutic needs across several illnesses. There are significant investments in regulatory work and documentation to have these products approved under the Danish Pilot Programme, and today’s milestone is another proof point for the unique skills and experiences of our regulatory team to meet the strict requirements of the Danish Medicines Agency. This fortifies Stenocare’s leading position in the Danish market.”

STENOCARE expands in Australia

Stenocare is a supplier of prescription-based medical cannabis oil products in several markets and has been present in the Australian market since Q4 2022. According to the National Drug Strategy Household Survey and Australian regulator report, the Australian medical …

STENOCARE expands in Australia

Stenocare is a supplier of prescription-based medical cannabis oil products in several markets and has been present in the Australian market since Q4 2022. According to the National Drug Strategy Household Survey and Australian regulator report, the Australian medical cannabis market size is approximately 450,000 patients (Dec-2023). The projected market growth rate is 15.77% CAGR from 2023 to 2028 with a forecasted market size US $791.60M by 2028 (Statista; Jul-2023). 

Under a new agreement, Stenocare has partnered with Quest Biotech Pharma ("QBP"), a highly specialized Australian pharmaceutical company. The shared objective is to expand the reach to more patients through qualified prescribing doctors. QBP partners with an holistic tele healthcare clinic - TeleDocs Clinic - serving patients with convenient access to medical care services nationwide from the Eastern States to Western Australia. This is a vast area with services open to all of Australia’s 26.6 million population. The mutual goal is to capture market share and achieve a 100% growth in the sales run rate of Stenocare-branded products in 2024.

Read the full announcement here: 2493725.pdf (cision.com)

GERMANY: STENOCARE is expanding outside Denmark with more prescription-based products.

Germany is the largest market in Europe with approx. 230.000 patients (out of 87 mill citizens) and projected sales of Euro 1 billion in 2027 – according to industry analysts.

STENOCARE has entered Germany with a …

GERMANY: STENOCARE is expanding outside Denmark with more prescription-based products.

Germany is the largest market in Europe with approx. 230.000 patients (out of 87 mill citizens) and projected sales of Euro 1 billion in 2027 – according to industry analysts.

STENOCARE has entered Germany with a THC10/CBD10 medical cannabis oil product together with an local experienced pharma partner.

CEO of Stenocare, Thomas Skovlund Schnegelsberg comments: “We have prepared for our German entry for a long time. Now we are ready to ship the first medical cannabis oil products to German patients with our local partner. This is a huge milestone for the company. Germany has grown significantly since the legalization in 2017, and it feels like jumping onto a train in full motion. We are humbled by its size and momentum, but we have a solid strategy to help us onboard and to enjoy the ride.”

Read the full announcement here: 2392760.pdf (cision.com)